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Abstract: Epigenetic aging has been found to be associated with a number of phenotypes and
diseases. A few studies have investigated its effect on lung function in relatively older people.
However, this effect has not been explored in the younger population. This study examines whether
lung function in adolescence can be predicted with epigenetic age accelerations (AAs) using machine
learning techniques. DNA methylation based AAs were estimated in 326 matched samples at two
time points (at 10 years and 18 years) from the Isle of Wight Birth Cohort. Five machine learning
regression models (linear, lasso, ridge, elastic net, and Bayesian ridge) were used to predict FEV1
(forced expiratory volume in one second) and FVC (forced vital capacity) at 18 years from feature
selected predictor variables (based on mutual information) and AA changes between the two time
points. The best models were ridge regression (R2 = 75.21% ± 7.42%; RMSE = 0.3768 ± 0.0653) and
elastic net regression (R2 = 75.38% ± 6.98%; RMSE = 0.445 ± 0.069) for FEV1 and FVC, respectively.
This study suggests that the application of machine learning in conjunction with tracking changes in
AA over the life span can be beneficial to assess the lung health in adolescence.
Keywords: lung function; epigenetic aging; machine learning; feature selection; hyperparameter
tuning
1. Introduction
In recent years, the concept of biological aging, as opposed to chronological aging, has gained
considerable popularity in understanding the aging process due to its stronger relation with phenotypes
and diseases [1]. DNA methylation (DNAm), an epigenetic process, can provide biomarkers to estimate
biological aging, known as “epigenetic aging”. There are several methods available to estimate epigenetic
aging [2–6], and among them, the Horvath method for epigenetic age estimation (DNAmAge) is
used widely and has shown high accuracy, with an average correlation > 0.90 with chronological
age [4]. Age acceleration (AA) is the difference between epigenetic age and chronological age, and both
DNAmAge and AA are highly correlated with chronological age. However, another epigenetic age
acceleration measure calculated from the residuals of regression (AAres), between epigenetic and
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chronological ages, is not correlated with chronological age and is thought to represent true biological
effects on age related phenotypes. In addition, another related measure is the intrinsic epigenetic age
acceleration (IEAA), which is independent of age related changes of the cellular composition of blood [7].
Several recent studies, using the Horvath method, have found that age acceleration is associated with a
number of diseases and phenotypes, such as obesity [8], Alzheimer’s disease [9], Down’s syndrome [10],
Huntington disease [11], HIV [12], Parkinson’s disease [13], earlier menopause [14], and overall
mortality [15]. Studies have also shown that lung function can be influenced by epigenetic age
accelerations as quantified in peripheral blood DNAm [16,17].
Lung development is a continuous process from childhood to adolescence [18]. Low adult lung
function can be the result of poor growth in childhood, which may cause excessive decline in adult
life [19], and it has been found, in many studies, that children with poor lung function also experience
reduced lung function in adulthood [20–24]. While lung function is dependent on age, gender, height,
and ethnicity [18], it can be influenced by both genetics [25] and environmental exposure [26–28].
Studies have shown that DNAm, measured in peripheral blood, is associated with lung functions [29].
Changes in DNAm from childhood to adolescence have been found to be associated with lung function
during adolescence in females [30]. Therefore, changes in DNAm aging from childhood to adolescence
may have potential effects on lung function.
To date, only two studies have explored the association of epigenetic aging and lung function.
Marioni et al. [16] examined the association of various physical measures with epigenetic aging in over
1000 elderly adults (mean age of 69 ± 0.83 years) in the 1936 Mid-Lothian Birth Cohort, which followed
up between three and six years. Lung function, considered as FEV1 (forced expiratory volume in one
second), showed a statistically weak (p-value = 0.05) association with DNAmAge with a small effect
size (<1 mL change in FEV1 per additional year of epigenetic aging), and epigenetic aging explained
only 0.33% of the variance in FEV1 decline. In contrast, Rezwan et al. [17] explored the association of
lung function in two cohorts, namely the Swiss study of Air Pollution and Lung and heart Disease in
Adults (SAPALDIA) and the European Community Respiratory Health Survey (ECRHS) from ALEC
(Aging Lungs in European Cohorts) project, at two time points and found that AA is cross-sectionally
associated with lower FEV1 (forced expiratory volume in one second) and FVC (forced vital capacity)
in females at the follow-up time point only. The findings were both statistically significant, and the
effect sizes were larger, for FEV1: between −5.00 mL and −3.02 mL and for FVC: between −8.06 mL
and −4.61 mL, in comparison to the previous study. However, both studies dealt with the association
of lung function in comparatively older adults, focusing on lung function decline, and no such work
has been undertaken to explore the effect of epigenetic age measures on the lung function development
from childhood to adolescence.
Machine learning approaches are increasingly in use to address healthcare problems. However,
to date, no study has been conducted to predict lung functions using machine learning approaches.
Few studies incorporated machine learning in lung function tests [31] and diseases related to lung
function, such as chronic obstructive pulmonary disease (COPD) and asthma [32,33]. Moreover, no work
has been done yet to leverage the power of machine learning by utilizing the effect of DNAmAge and
AAs on lung function.
As part of the Isle of Wight Birth Cohort (IOWBC), DNAm in peripheral blood and lung function
at ages 10 and 18 years were obtained. Therefore, the aim of the study was to explore the efficacy of the
use of machine learning regression models in predicting lung function for subjects at 18 years of age
using their epidemiological and epigenetic aging data from both 10 and 18 years of age.
2. Materials and Methods
2.1. Isle of Wight Birth Cohort
The IOWBC is a population birth cohort of 1536 newborns, recruited between 1989 and 1990 [34].
Informed consent for 1456 infants was obtained from the parents, and they were enrolled into the
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longitudinal study. Participants were followed up at 1 or 2, 4, 10, 18, and 26 years, and peripheral
blood samples were collected at birth (neonatal heel prick on Guthrie cards) and at 10, 18, and 26 years.
2.2. DNA Extraction and Microarray
DNA was extracted from peripheral blood samples for 326 matched 10 year and 18 year samples.
DNAm levels were measured using the Infinium HumanMethylation450 and Methylation EPIC
BeadChips from Illumina (Illumina, San Diego, CA, USA) for the 10 year and 18 year old samples,
respectively. The CPACOR (Control Probe Adjustment and reduction of global CORrelation) pipeline
was used for quality control and pre-processing DNAm data (β values) [35], and batch effect correction
was done using ComBat [36].
2.3. Measuring Epigenetic Aging
DNAmAge was calculated using the Horvath method, which uses 353 cytosine-phosphate-guanine
sites (CpGs) from the Illumina Infinium HumanMethylation450 Beadchip arrays. The missing CpG
sites in the EPIC array were imputed during DNAmAge calculation. Age acceleration residuals
(AAres) were obtained from a linear regression model by regression of DNAmAge on chronological
age and further adjusted for blood cell counts to calculate intrinsic epigenetic age acceleration
(IEAA). Age acceleration measures were estimated using an online calculator (available at https:
//dnamage.genetics.ucla.edu/new).
2.4. Feature Selection
FEV1 and FVC at age 18 were used as the outcome variables. Each subject’s sex, weight, height,
hay fever status, asthma status, eczema status, and smoking status at age 18, and FEV1 and FVC
at age 10 with AA, AAres, and IEAA at age 18 were used as features. Mutual information between
each feature and the target FEV1 and FVC at age 18, respectively, was calculated, and features whose
mutual information was > 0.1 were selected. The recursive feature elimination (RFE) method was
also undertaken and concurred with the same set of features that were obtained from the mutual
information (Table S1). Min-max normalisation was done on selected features before feeding this to the
regression model.
2.5. Machine Learning Model
Five machine learning regression models: linear, lasso, ridge regression, elastic net, and Bayesian
ridge regression, were used to predict FEV1 and FVC at age 18. The best subset of features from the
feature selection was used, and 10-fold cross-validation was performed along with fine-tuning the
hyperparameters using grid search, where applicable. To select the best alpha (hyperparameter that
controls the balances between minimizing the residual sum of squares vs. minimizing the sum of
squares of coefficients), the models were run for different ranges of alpha, and the best alpha was
empirically chosen to build the model. Further, age acceleration changes at 10 and 18 years were added
by taking differences between epigenetic age acceleration between two age groups (denoted as: AAdiff,
AAresdiff, and IEAAdiff).
3. Results
A total of 326 participants with matched data at 10 and 18 years were analysed. Descriptive statistics
are given in Table S2.
3.1. Feature Selection by Mutual Information Regression
For FEV1, four features were identified as the most important, namely height, sex, weight, at age 18,
and FEV1 at age 10 (Figure 1 and Table S3). AA, AAres, and IEAA exhibited lower mutual information
scores (0.041, 0.028, and 0.003, respectively).
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(F 1) t age 18. A mutual information score > 0.1 was used as threshold for selecting the
best features. AA, age acceleration; IEAA, intrinsic epigenetic age acceleration.
Similarly, for FVC, the same three features (height, sex, and weight) at age 18 and FVC at age 10
were identified as the most important (Figure S1 and Table S2). AA exhibited lower mutual information
scores (0.029), and AAres and IEAA had mutual information of zero.
3.2. Machine Learning Regression Models for FEV1
With the four best features (height, sex, and weight at age 18, and FEV1 at age 10) for FEV1, all the
regression models performed almost similarly after tuning the hyperparameter. However, the ridge
regression model (withα= 0.4) worked slightly better (R2 = 75.03%± 7.37% with RMSE = 0.378 ± 0.064)
than other methods (Table 1). As expected, based on the mutual information score, adding three age
acceleration measures (AA, AAres, and IEAA) with these four features did not improve the predictions
of FEV1 (Table S4).
Table 1. Results of five regression models predicting FEV1 using the best features.
Regression Model R2 RMSE
Linear 74.98 ± 7.45 0.3781 ± 0.06380
Lasso
(α = 0.0001) 74.99 ± 7.45 0.3801 ± 0.0519
Ridge
(α = 0.4) 75.03 ± 7.37 0.3780 ± 0.0639
Elastic Net
(α = 0.001) 75.00 ± 7.41 0.3781 ± 0.0640
Bayesian Ridge 75.01 ± 7.42 0.3780 ± 0.0639
The models were developed using the four best features (height, sex, and weight at age 18 and FEV1 at age 10) as
predictors of FEV1. Here, R2 = average goodness-of-fit measure for regression models represented as a percentage
and RMSE = average root mean squared error.
Changes of AA between the two time points (AAdiff, AAresdiff, and IEAAdiff) were added with
the four predictive features. Although none of the age acceleration differences were found significant
during feature selection using mutual information regression, adding AAdiff with the other important
features showed slight improvement in predicting FEV1. The best performer was the ridge regression
model (R2 = 75.21% ± 7.42% with RMSE = 0.3768 ± 0.0653) (Table 2 and Table S5).
3.3. Machine Learning Regression Models for FVC
For FVC, using the four best features (height, sex, and weight at age 18 and FVC at age
10), all the regression models performed with similar efficacy after tuning the hyperparameters.
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The elastic net regression model (with α = 0.0025) performed slightly better (R2 = 75.35% ± 6.88%
with RMSE = 0.445 ± 0.064) than the other methods (Table 3). Adding three age acceleration measures
(AA, AAres, and IEAA) with these four features did not improve the predictions of FVC (Table S6).
Table 2. Results of five regression models predicting FEV1 using the best features and AAdiff.
Regression Model R2 RMSE
Linear 75.16 ± 7.49 0.3770 ± 0.0652
Lasso
(α = 0.0001) 75.16 ± 7.49 0.3770 ± 0.0652
Ridge
(α = 0.4) 75.21 ± 7.42 0.3768 ± 0.0653
Elastic Net
(α = 0.001) 75.16 ± 7.49 0.3770 ± 0.0653
Bayesian Ridge 75.19 ± 7.46 0.3768 ± 0.0652
The models were developed using the four best features (height, sex, and weight at age 18 and FEV1 at age 10)
with AAdiff as predictors of FEV1. Here, AAdiff = AA at 18 – AA at 10, R2 = average goodness-of-fit measure for
regression models represented as a percentage and RMSE = average root mean squared error.
Table 3. Results of five regression models predicting FVC using the best features.
Regression Model R2 RMSE
Linear 75.24 ± 7.10 0.4455 ± 0.0692
Lasso
(α = 0.0001) 75.25 ± 7.08 0.4456 ± 0.0680
Ridge
(α = 0.4) 75.24 ± 7.00 0.4458 ± 0.0673
Elastic Net
(α = 0.0025) 75.35 ± 6.88 0.4450 ± 0.0673
Bayesian Ridge 75.25 ± 7.07 0.4456 ± 0.0678
The models were developed using four best features (height, sex, weight at age 18 and FVC at age 10) as
predictors of FVC. Here, R2 = average goodness-of-fit measure for regression models represented as percentage and
RMSE = average root mean squared error.
While adding changes of AA (AAdiff, AAresdiff, and IEAAdiff) with the four predictive features,
showed almost similar prediction capacity for FVC (Table S7). The best performer was Elastic net
regression model (R2 = 75.38% ± 6.98% with RMSE = 0.445 ± 0.069) (Table 4).
Table 4. Results of five regression models predicting FVC using best features and AAdiff.
Regression Model R2 RMSE
Linear 75.26 ± 7.14 0.4456 ± 0.0693
Lasso
(α = 0.0001) 75.27 ± 7.12 0.4456 ± 0.0692
Ridge
(α = 0.4) 75.28 1 7.12 0.4455 ± 0.0691
Elastic Net
(α = 0.0025) 75.38 ± 6.98 0.4448 ± 0.0690
Bayesian Ridge 75.28 ± 7.13 0.4455 ± 0.0692
The models were developed using the four best features (height, sex, and weight at age 18 and FVC at age 10) with
AAdiff as predictors of FVC. Here, AAdiff = AA at 18 - AA at 10, R2 = average goodness-of-fit measure for regression
models represented as a percentage and RMSE = average root mean squared error.
3.4. Effect of Alpha on the Ridge Regression Model
The choice of α affects the mean R2 values for the regression models. Figure 2a shows how the
choice of α affects the mean R2 values for ridge regression for the FEV1 prediction, and the best R2
value was achieved with α = 0.4. Similar behaviour was noticed for the elastic net regression for the
FVC prediction (Figure 2b).
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lung function decli e rather than development. The articipants from the Mid-Lothian Birth Co ort
study were 70 years at baseline and 76 y ars at follow-up, nd participants from the ALEC project
were 37 t 61 years at baseline and 48 to 70 years at follow-up, whereas partici ants from IOWBC were
matched samples at 10 and 18 years.
I this study, changes of epig netic age acceleration, b tween 10 years and 18 years,
were incorporated with the most informative features from the featur selection technique to develop
the best regression models. Previous studies have found height, weight, and sex to i rt t
r i t r f l f ti [ , , ]. i t fir t r i r ti l
f ti t li ti i t ( f ), i fi t ffi f i l i i
i tif i predictors for lung function. Our study uggests that changes in epi netic age acc leration
betw en 10 and 18 years can improve the prediction of FEV1 and FVC at 8 years of age. Based on the
prediction performances of the five selected regression models, it can be postulated that any of these
supervis d machine l arning techniques can be used for lung function prediction.
fine-tuning of hyperpar met rs always plays a crucial role in the efficacy of a machine le rni g
t chnique, and w showed t at the choice of the hyperparamete (α) changes the prediction result
drastically. Therefore, a grid search was performed for identifying the most optimized parameters for
the models to achieve the best prediction performance. This is evident from the higher average R2 and
lower RMSE values of each regression model. The best models can explain 75.16% and 75.38% of the
variance for FEV1 and FVC, respectively, through weight, height, sex at 18 years, and lung function
at 10 years in conjunction with the changes of epigenetic age acceleration between 10 and 18 years.
The RMSE values are also very low for each model (0.3768 ± 0.0653 and 0.4448 ± 0.0690, for FEV1 and
FVC model, respectively).
Our study has some limitations. Firstly, due to a relatively smaller sample size (n = 326),
ten-fold cross-validation was used to generate average performance measures of the models rather
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than using a hold-out test set. However, the cross-validation method performs better to break the bias
variance trade-off in small datasets [39]. Furthermore, we note that min-max normalisation on all the
data was done before the cross-validation step, whereas, ideally, it is expected that normalization should
be done at each step of the cross-validation, learning the normalization only on the training folds and
applying it to the test fold. Considering the small dataset and examining that this has virtually no effect
on overall performance, this was not followed. Secondly, epigenetic age derived from blood was used
rather than lung tissue. However, successful use of epigenetic aging measured from blood is evident in
a number of other non-blood related diseases and phenotypes, such as: developmental disorders [40],
lung cancer [41], and metabolic syndrome [8]. Additionally, physiological changes, such as hormonal
changes during adolescence, were not considered. Moreover, sex-stratified analysis, for lung function,
has proven informative in other studies [17,30], and therefore, this could be implemented in this study
as well. However, this would further lower the samples size (43.25% female) and may be impractical
for this study.
In conclusion, while the full impact of epigenetic age acceleration is still unknown from DNA
methylation measures, this study suggests that it can be utilised as one of the potential factors to predict
adolescent lung function. It also suggests that the application of machine learning in conjunction with
tracking changes in epigenetic age acceleration over the life span can be beneficial to assess lung health
in adolescent and have the potential to be extended to adults.
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